Zimmer Biomet's Mixed Q3: Analysts' Positive Outlook
Update: 2025-11-12
Description
Zimmer Biomet, a medical technology company specializing in orthopedic surgery products, has seen a significant drop in its stock price, with a sixteen percent decline this year and nearly twenty percent in the last twelve months. Despite this, the companys adjusted earnings per share grew by over nine percent, beating analysts expectations. The consensus among analysts is a Moderate Buy, with several recommending a Strong Buy, and an average price target of one hundred three dollars and forty-eight cents, suggesting a potential sixteen point nine percent increase from current levels.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
